Advertisement

Topics

Search Results for "Galderma Company Rpofile"

03:26 EST 5th December 2016 | BioPortfolio

Matching Channels

Medtronic

With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

MediciGlobal is a specialty patient recruitment-retention organization serving the clinical trials industry

MediciGlobal is a specialty patient recruitment-retention organization serving the clinical trials industry. For more than two decades, the company has led the industry in developing innovative p...

Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Senior Vigilance Manager – Galderma

Galderma is a global company delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime.With more than 5,500 employees, Galderma has three units focus...

Galderma secures FDA approval for Differin Gel as OTC treatment for acne

Galderma's U.S. affiliate, Galderma Laboratories received approval from the U.S. Food and Drug Administration (FDA) for Differin Gel (adapalene gel 0.1%) as an over-the-counter (OTC) treatment for acn...

Galderma licenses nemolizumab from Chugai

Chugai Pharmaceuticals and Switzerland’s Galderma have entered into a global license agreement for…

Chugai, Galderma sign license deal for skin disorder treatment

Chugai Pharmaceutical granted Galderma Pharma an exclusive worldwide license for CIM331, or nemolizumab, a humanized monoclon -More- 

Galderma licenses Chugai's atopic dermatitis candidate nemolizumab

Galderma SA licensed worldwide development and marketing rights (except in Japan and Taiwan) to Chugai Pharmaceutical Co. Ltd.'s dermatology candidate nemolizumab (CIM331).

Galderma Steps Into Biologics With Chugai Eczema Antibody

Galderma has acquired most global rights to a first-in-class antibody from Chugai that will both strengthen the Swiss skin specialist's...   

Chugai, Galderma sign license deal for nemolizumab

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Galderma Pharma S.A. today announced that they have entered into a global license agreement for “nemolizumab” (CIM331) the anti-IL-31 receptor A h...

Chugai und Galderma geben weltweite Lizenzvereinbarung für Nemolizumab (CIM331) bekannt, ein neues biologisches Arzneimittel für Hautkrankheiten

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) und Galderma Pharma S.A. gaben heute den Abschluss einer weltweiten Lizenzvereinbarung bekannt für "Nemolizumab" (CIM331), dem humanisierten, monoklona...

Matching PubMed Articles

The History of Articulators: The Contributions of Rudolph L. Hanau and His Company-Part II.

This article is an historical overview of the Hanau Engineering Company from the time of Rudolph Hanau's death in 1930 to the present. It explores the development of many articulators intended both fo...

Poetry's Company: Where Medicine Leaves Us Alone.

Strategies for Health System Innovation After Gobeille v Liberty Mutual Insurance Company.

Intergenerational Cycles of Trauma and Violence: An Attachment and Family Systems Perspectiveby Pamela C. Alexander; New York, W. W. Norton and Company, 2015, 370 pages.

A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.

U.S. Food and Drug Administration-approved formulations of botulinum toxin include onabotulinumtoxinA (Botox; Allergan, Inc., Irvine, Calif.), abobotulinumtoxinA (Dysport; Galderma Pharma S.A., Lausan...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement